Annals of Oncology 7:189-195, 1996
© 1996 European Society for Medical Oncology
research-article |
On the receiving end V: Patient perceptions of the side effects of cancer chemotherapy in 1993
1Medical Psychology Unit, University of Sydney NSW, Australia
2Department of Medical Oncology, Royal Prince Alfred Hospital NSW, Australia
3Department of Cancer Medicine, University of Sydney NSW, Australia
Prof. Alan Coates Department of Medical Oncology Royal Prince Alfred Hospital Camperdown, NSW, 2050 Australia
Background: A study conducted in 1983 to identify and rank the symptoms experienced by patients receiving cancer chemotherapy reported that vomiting and nausea were the most important symptoms experienced. With the advent of new antiemetic regimens and changes in cancer chemotherapy, it was anticipated that changes may have occurred in patient perception of symptoms. The study was therefore repeated in 1993.
Patients and methods: One hundred and fifty-five cancer patients receiving chemotherapy at a large urban teaching hospital participated in the study. Patients selected from cards listing symptoms all those experienced and the five most troublesome.
Results: Patients reported experiencing an average of 20 symptoms (13 physical and 7 psychosocial). Nausea was reported as the most severe symptom followed by tiredness and loss of hair. Vomiting, which was the most severe symptom in 1983, now ranked 5th. Differences were detected in the symptoms experienced and reported as most severe, between chemotherapy regimens, between older and younger patients and between males and females.
Conclusions: The results suggest a reduction in the severity of some symptoms experienced while receiving chemotherapy and a shift from concerns about physical to psychosocial issues.
cancer, chemotherapy, psychology, side effects
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Camerini, C. Valsuani, F. Mazzoni, O. Siclari, C. Puccetti, S. Donati, M. Rondini, G. Tartarelli, P. Puccinelli, F. Di Costanzo, et al. Phase II trial of single-agent oral vinorelbine in elderly (>=70 years) patients with advanced non-small-cell lung cancer and poor performance status Ann. Onc., November 13, 2009; (2009) mdp525v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Hesketh Penny Wise, Dollar Foolish Approach to Antiemetic Use May Compromise Patient Care J. Oncol. Pract, September 1, 2009; 5(5): 221 - 222. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Steinbach, T. Hummel, C. Bohner, S. Berktold, W. Hundt, M. Kriner, P. Heinrich, H. Sommer, C. Hanusch, A. Prechtl, et al. Qualitative and Quantitative Assessment of Taste and Smell Changes in Patients Undergoing Chemotherapy for Breast Cancer or Gynecologic Malignancies J. Clin. Oncol., April 10, 2009; 27(11): 1899 - 1905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Shih, H. S. Wan, and A. Chan Clinical Predictors of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer Patients Receiving Adjuvant Doxorubicin and Cyclophosphamide Ann. Pharmacother., March 1, 2009; 43(3): 444 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Harcourt and H. Frith Women's Experiences of an Altered Appearance during Chemotherapy: An Indication of Cancer Status J Health Psychol, July 1, 2008; 13(5): 597 - 606. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Georgy, J. Neceskas, and S. Goodin Antiemetic care for patients with breast cancer: Focus on drug interactions and safety concerns Am. J. Health Syst. Pharm., November 1, 2007; 64(21): 2227 - 2236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ezzo, A. Vickers, M. A. Richardson, C. Allen, S. L. Dibble, B. Issell, L. Lao, M. Pearl, G. Ramirez, J. A. Roscoe, et al. Acupuncture-Point Stimulation for Chemotherapy-Induced Nausea and Vomiting J. Clin. Oncol., October 1, 2005; 23(28): 7188 - 7198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Gralla Quality-of-Life Considerations in Patients with Advanced Lung Cancer: Effect of Topotecan on Symptom Palliation and Quality of Life Oncologist, December 1, 2004; 9(suppl_6): 14 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Kris Why Do We Need Another Antiemetic? Just Ask. J. Clin. Oncol., November 15, 2003; 21(22): 4077 - 4080. [Full Text] [PDF]
|
|
|
|
|
|
R. de Wit, J. Herrstedt, B. Rapoport, A.D. Carides, G. Carides, M. Elmer, C. Schmidt, J.K. Evans, and K.J. Horgan Addition of the Oral NK1 Antagonist Aprepitant to Standard Antiemetics Provides Protection Against Nausea and Vomiting During Multiple Cycles of Cisplatin-Based Chemotherapy J. Clin. Oncol., November 15, 2003; 21(22): 4105 - 4111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Tchen, H. G. Juffs, F. P. Downie, Q.-L. Yi, H. Hu, I. Chemerynsky, M. Clemons, M. Crump, P. E. Goss, D. Warr, et al. Cognitive Function, Fatigue, and Menopausal Symptoms in Women Receiving Adjuvant Chemotherapy for Breast Cancer J. Clin. Oncol., November 15, 2003; 21(22): 4175 - 4183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bernhard, R. Maibach, B. Thurlimann, C. Sessa, and M. S. Aapro Patients' Estimation of Overall Treatment Burden: Why Not Ask the Obvious? J. Clin. Oncol., January 1, 2002; 20(1): 65 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Cella, K. Davis, W. Breitbart, and G. Curt Cancer-Related Fatigue: Prevalence of Proposed Diagnostic Criteria in a United States Sample of Cancer Survivors J. Clin. Oncol., July 15, 2001; 19(14): 3385 - 3391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Campos, J. R. Pereira, R. R. Reinhardt, C. Carracedo, S. Poli, C. Vogel, J. Martinez-Cedillo, A. Erazo, J. Wittreich, L.-O. Eriksson, et al. Prevention of Cisplatin-Induced Emesis by the Oral Neurokinin-1 Antagonist, MK-869, in Combination With Granisetron and Dexamethasone or With Dexamethasone Alone J. Clin. Oncol., March 15, 2001; 19(6): 1759 - 1767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Gralla Silk Purse in Atlanta: A Commentary on SWOG 9509, An Advanced Non-Small Cell Lung Cancer Trial Oncologist, June 1, 1999; 4(3): 188 - 190. [Full Text]
|
|
|
|
|
|
P. J. Hesketh Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice Oncologist, June 1, 1999; 4(3): 191 - 196. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. H N Tattersall and H. Thomas Recent advances: Oncology BMJ, February 13, 1999; 318(7181): 445 - 448. [Full Text]
|
|
|
|
 |
|
 R. M. Navari, R. R. Reinhardt, R. J. Gralla, M. G. Kris, P. J. Hesketh, A. Khojasteh, H. Kindler, T. H. Grote, K. Pendergrass, S. M. Grunberg, et al. Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1-Receptor Antagonist N. Engl. J. Med., January 21, 1999; 340(3): 190 - 195. [Abstract] [Full Text] [PDF]
|
|